Media advisory: Experts from Glenn Biggs Institute at UT Health San Antonio available to discuss new Alzheimer’s drug

June 9, 2021

The U.S. Food and Drug Administration (FDA) on Monday, June 7, approved the drug aducanumab for the treatment of Alzheimer’s disease, which affects 6.2 million Americans. Sudha Seshadri, MD, professor of neurology at UT Health San Antonio and director of the university’s Glenn Biggs Institute for Alzheimer’s and Neurodegenerative Diseases, issued the following statement: “We are excited that a drug, aducanumab (Aduhelm, from Biogen), has been approved by the FDA for treatment of persons with early symptoms due to Alzheimer’s disease. This is the first new drug approved for Alzheimer’s in two decades.”

Alzheimer's patients



Discover Magazine: Fight or flight? Why our caveman brains keep getting confused

April 16, 2021

Dr. Sudha Seshadri, professor of neurology and director of the Glenn Biggs Institute for Alzheimer’s and Neurodegenerative Diseases, explains the link between neurodegenerative diseases and high cortisol levels in this Discover Magazine article. The story mentions that her research published in the journal Neurology, has shown that those with higher morning cortisol levels are more […]


News 4: Local doctors research if cholesterol pill can keep you healthy as you age

April 7, 2021

In this News 4 segment, Dr. Sara Espinoza, Geriatrics, Gerontology and Palliative Medicine, explained the clinical trial PREVENTABLE, an NIH-funded study of the Barshop Institute. The study will investigate whether taking atorvastatin, a drug commonly used to lower cholesterol also called Lipitor®, can help adults age 75 and older maintain health by preventing dementia, disability […]



Faculty member selected for diversity leadership program

March 5, 2021

Eduardo Marques Zilli, MD, assistant professor and neurologist with the Glenn Biggs Institute for Alzheimer’s and Neurodegenerative Diseases at UT Health San Antonio, was recently selected to take part in the 2021 America Academy of Neurology Diversity Leadership Program.